Anxiolytic use of the known Bromantane molecule — RU2175229C2
S. B. Seredenin, M. A. Yarkova, B. A. Badyshtov, B. M. Pyatin, N. I. Avdyunina, I. S. Morozov, T. A. Voronina, G. G. Neznamov · 2001 · Russian patent RU2175229C2
What does this source report?
Identifies Ladasten as the known Bromantane molecule and cites earlier psychostimulant certificate 860446 and immunostimulant patent 1826906.
- Population and setting
- Patent describing a new proposed use of an existing molecule
- Evidence type
- Patent / reported experiments
- Preparation
- See the original report; formulation details require verification.
- Source language
- Russian
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- A new-use patent is not evidence of clinical effectiveness or regulatory status.
- The earlier certificates are cited here; their original priority documents remain archival targets.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
Original patent text checked, including identity and references to the earlier certificates.
Recorded source-check date: 2026-09-29. This date does not imply a completed systematic review.
Cite and trace this record
Original source: S. B. Seredenin, M. A. Yarkova, B. A. Badyshtov, B. M. Pyatin, N. I. Avdyunina, I. S. Morozov, T. A. Voronina, G. G. Neznamov. Anxiolytic use of the known Bromantane molecule — RU2175229C2 Russian patent RU2175229C2 2001.
Molekul research summary: https://molekul.io/research/acto-ladasten-patent. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry